Evidence map›Paper›PMID 40133984›Full record

ArticleJournal of breast cancer2025

Molecular Characteristics of Prognosis and Chemotherapy Response in Breast Cancer: Biomarker Identification Based on Gene Mutations and Pathway.

Liyan Li, Hongwei Lyu, Qian Chen, Yating Bai, Jing Yu, Ruigang Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liyan Li *Beijing Pinggu District Maternal and Child Health Care Hospital, Beijing, China.ORCID https://orcid.org/0009-0007-7011-0984
Hongwei Lyu *Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0003-3321-3531
Qian ChenThorgene Co., Ltd., Beijing, China.ORCID https://orcid.org/0000-0003-3697-5267
Yating BaiThorgene Co., Ltd., Beijing, China.ORCID https://orcid.org/0009-0001-7019-0909
Jing YuCancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. yujing026@ccmu.edu.cn.ORCID https://orcid.org/0000-0001-9521-261X
Ruigang CaiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. cairuigang@cicams.ac.cn.ORCID https://orcid.org/0009-0003-1652-671X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to investigate the molecular characteristics associated with better prognosis in breast cancer.

methodsWe performed targeted sequencing of 962 genes in 56 samples, categorizing them into long-term and short-term survival groups as well as chemotherapy-sensitive and chemotherapy-resistant groups for further analyses.

resultsThe results indicated that the tumor mutational burden values were significantly higher in the short-term survival and chemotherapy-resistant groups (

conclusionThis study, through intergroup comparative analysis, found that immunotherapy (using programmed death 1/programmed death-ligand 1 inhibitors) may improve the prognosis of patients with short survival and chemotherapy resistance. Additionally, the study revealed that mutations in

Indexed as

Breast NeoplasmsDrug TherapySequence Analysis, DNA

Identifiers

PMID40133984
PMCPMC12046353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.